VXRT:OTCMKTS
Vaxart Inc
$0.46
arrow_downward
-0.36%(-0.0016) 1D
Okt 14, 10:21:24 AM GMT-4 · USD
search
Lahat ng simbolo
| Simbolo | Presyo | Palitan | % ng Pagbabago |
|---|
insights_autoBumubuo ng mga nangungunang insight para sa VXRT...
Buksan
$0.46
Mataas
$0.46
Mababa
$0.46
Mkt. cap
109.68M
Avg. na dami
260.92K
Dami
58.64K
P/E ratio
2.79
Mataas nang 52-wk
$0.84
Mababa nang 52-wk
$0.30
EPS
$0.16
Beta
1.05
Mga natitirang share
242.84M
Bilang ng mga empleyado
65
Buksan
$0.46
Mataas
$0.46
Mababa
$0.46
Mkt. cap
109.68M
Avg. na dami
260.92K
Dami
58.64K
P/E ratio
2.79
Mataas nang 52-wk
$0.84
Mababa nang 52-wk
$0.30
EPS
$0.16
Beta
1.05
Mga natitirang share
242.84M
Bilang ng mga empleyado
65
Mga balita at kwento
Mula sa mga source sa web at partner sa balita
Bloomberg.com
·
16 oras ang nakalipas
Stocks, Bonds Fall as CPI Data Fuel Fed-Hike Bets: Markets Wrap
Yahoo Finance
·
6 araw ang nakalipas
These 7 major S&P 500 stocks need to rally at least 200% to reclaim their peaks
The Guardian
·
1 linggo ang nakalipas
S&P 500 and Nasdaq surge to record highs after AI chipmaker rally
TheStreet
·
1 buwan ang nakalipas
UBS revamps S&P 500 target for rest of 2026
Profile
Vaxart, Inc. is an American biotechnology company focused on the discovery, development, and commercialization of oral recombinant vaccines administered using temperature-stable tablets that can be stored and shipped without refrigeration, eliminating the need for needle injection. Its development programs for oral vaccine delivery include prophylactic, enteric-coated tablet vaccines for inhibiting norovirus, seasonal influenza, respiratory syncytial virus, and human papillomavirus. It was founded in 2004 by Sean Tucker. Originally incorporated as West Coast Biologicals, Inc. in California in 2004, the company later changed its name to Vaxart, Inc. in July 2007, after reincorporating in Delaware. A significant development in the company's history was the reverse merger with Aviragen Therapeutics, Inc. on February 13, 2018, which led to Vaxart becoming a wholly owned subsidiary of Aviragen. Post-merger, the company continued as Vaxart, Inc.
Vaxart's development portfolio includes a range of oral vaccines targeting infectious diseases such as norovirus, COVID-19, and seasonal influenza, as well as therapeutic vaccines like those targeting HPV. Wikipedia
Tungkol sa Vaxart Inc
CEO-
Mga Empleyado65
ItinatagMar 2004
HeadquartersSouth San Francisco, California, Estados Unidos
Sektor-
Websitevaxart.com